Chimeric Therapeutics (CHM) Stock Overview
A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
CHM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Chimeric Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.20 |
| 52 Week High | AU$0.90 |
| 52 Week Low | AU$0.10 |
| Beta | 0.85 |
| 1 Month Change | 0% |
| 3 Month Change | -20.00% |
| 1 Year Change | -55.56% |
| 3 Year Change | -97.01% |
| 5 Year Change | -99.26% |
| Change since IPO | -99.32% |
Recent News & Updates
Shareholder Returns
| CHM | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | 0.8% |
| 1Y | -55.6% | -39.8% | 14.1% |
Return vs Industry: CHM underperformed the Australian Biotechs industry which returned -39.8% over the past year.
Return vs Market: CHM underperformed the Australian Market which returned 14.1% over the past year.
Price Volatility
| CHM volatility | |
|---|---|
| CHM Average Weekly Movement | 72.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 10.7% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 4.6% |
Stable Share Price: CHM's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: CHM's weekly volatility has increased from 45% to 72% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Rebecca McQualter | www.chimerictherapeutics.com |
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors.
Chimeric Therapeutics Limited Fundamentals Summary
| CHM fundamental statistics | |
|---|---|
| Market cap | AU$8.84m |
| Earnings (TTM) | -AU$18.79m |
| Revenue (TTM) | AU$9.75m |
Is CHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHM income statement (TTM) | |
|---|---|
| Revenue | AU$9.75m |
| Cost of Revenue | AU$846.76k |
| Gross Profit | AU$8.90m |
| Other Expenses | AU$27.69m |
| Earnings | -AU$18.79m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 91.32% |
| Net Profit Margin | -192.71% |
| Debt/Equity Ratio | 0% |
How did CHM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/21 18:02 |
| End of Day Share Price | 2026/04/21 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chimeric Therapeutics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hunter Diamond | Diamond Equity Research LLC |
| Maxim Jacobs | Edison Investment Research |
| null null | Lodge Partners Pty Ltd. |